Engineered immune cells to target SARS-CoV2
Provided herein are, inter alia , methods, compositions and kits for treating or preventing coronaviruses, e.g., SARS-CoV-2. Also included herein are kits for treating or preventing coronaviruses, e.g., SARS-CoV-2.
1 . An engineered immune cell expressing a chimeric antigen receptor (CAR) polypeptide comprising an extracellular banana lectin (BanLec) domain, wherein the CAR polypeptide comprises an amino acid sequence having at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity with an amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO:9, or SEQ ID NO:11.
2 . The engineered immune cell of claim 1 , wherein the CAR polypeptide comprises an amino acid sequence having 95, 96, 97, 98, 99 or 100% identity with an amino acid sequence of SEQ ID NO: 6, SEQ ID NO:7, SEQ ID NO:9, orcv SEQ ID NO:11.
3 . The engineered immune cell of claim 1 , wherein the CAR polypeptide comprises an amino acid sequence having 99 or 100% identity with the amino acid sequence of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11.
4 . A method of preventing or treating a viral infection, the method comprising: administering to a subject suffering from or susceptible to a viral infection an effective amount of immune cells of claim 1 .
5 . The method of claim 4 , wherein the viral infection comprises a coronavirus infection.
6 . The method of claim 4 , wherein the viral infection comprises severe acute respiratory syndrome coronavirus 2 (SARS-COV-2).
7 . The method of claim 4 , wherein the viral infection comprises a retrovirus infection.
8 . The method of claim 4 , further comprising administering an additional, distinct antiviral agent to the subject.
9 . The method of claim 4 , wherein the mammal is a human.
10 . The method of claim 4 , wherein the cells are administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
11 . A method of preventing or treating a viral infection, the method comprising: providing a composition comprising a population of engineered immune cells of claim 1 , administering the composition to the subject, and thereby preventing or treating the viral infection.
12 . A kit comprising a population of engineered immune cells of claim 1 .
13 . A method of preventing or treating cells that have been infected by a virus, the method comprising: administering to virally infected cells an effective amount of immune cells of any one of claim 1 .
14 . A method of treating cells that have been infected by a virus, the method comprising: providing a composition comprising a population of engineered immune cells of claim 1 , administering the composition to virally infected cells, and thereby preventing or treating the viral infection in the cells.
15 . An engineered immune cell expressing a chimeric antigen receptor (CAR) polypeptide comprising an extracellular banana lectin (BanLec) domain, wherein the CAR polypeptide is encoded by a sequence having at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity with SEQ ID NO: 8 or SEQ ID NO: 10.
16 . The engineered immune cell of claim 15 , wherein the CAR polypeptide is encoded by a sequence having 95, 96, 97, 98, 99 or 100% identity with SEQ ID NO: 8 or SEQ ID NO:10.
17 . The engineered immune cell of claim 15 , wherein the CAR polypeptide is encoded by a sequence having 99 or 100% identity with SEQ ID NO:8 or SEQ ID NO:10.